Progen Co. Ltd.

As of December 31, 2025, Progen Co. Ltd. carries a market capitalization of 176.68B, placing it among publicly traded companies globally. Its enterprise value stands at 261.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Progen Co. Ltd. has 23.43M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 125.76, and the price-to-book ratio stands at 4.19.

These figures are as of December 31, 2025. The EV/Sales ratio of 295.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 261.35B versus a market cap of 176.68B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Progen Co. Ltd. maintains a current ratio of 0.10, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 193.87, indicating elevated leverage, while an interest coverage ratio of -4.11 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Progen Co. Ltd. posted a negative return on equity (ROE) of -46.59, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -13.12, reflecting losses generated across the asset base.

Over the twelve months ended December 31, 2025, Progen Co. Ltd. recorded 315.04M in income tax expense. The company reported a pretax loss of -19.78B and -20.09B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Progen Co. Ltd.'s stock has declined approximately 66.42% over the past 52 weeks. The 50-day moving average sits at 2,485.30, while the 200-day moving average is 4,383.73.

Over the twelve months ended December 31, 2025, Progen Co. Ltd. generated 884.75M in revenue and converted that into -20.09B in net income, yielding earnings per share of -1,361.52. EBITDA reached -16.27B, while operating income came in at -17.16B.

As of December 31, 2025, Progen Co. Ltd. holds 8.88B in cash and equivalents against 89.52B in total debt, resulting in a net debt position of 88.96B. Total book value stands at 42.14B, with working capital of -108.78B providing operational flexibility.

Progen Co. Ltd. produced -21.73B in operating cash flow over the twelve months ended December 31, 2025. After subtracting -27.49B in capital expenditures, free cash flow totaled -49.22B - equivalent to -3,335.38 per share.

Over the twelve months ended December 31, 2025, Progen Co. Ltd. posted a gross margin of 95.04, reflecting its pricing power and cost economics. The operating margin of -1,939.36 and net profit margin of -2,270.89 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -44.24: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -28.13, meaning Progen Co. Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, Progen Co. Ltd. has an Altman Z-Score of -0.78, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.